Skip to main content
NVDA-2.39%AAPL+2.31%GOOGL+0.10%MSFT-0.02%AMZN+0.06%TSM-0.72%SPCX+1.69%AVGO-0.04%META+0.40%TSLA-0.45%SKHY-3.99%MU-4.17%BRK-B-0.06%LLY+0.40%JPM-0.38%AMD-2.33%WMT+0.16%V-0.25%XOM-0.26%ASMLa-1.56%JNJ-0.22%INTC-4.20%MA-0.59%0700.HK-1.94%ORCL-2.03%1398.HK+0.79%BAC-0.26%ABBV+0.52%CSCO-0.44%CVX-0.51%COST-0.10%LRCX-3.66%KO+0.59%CAT-0.99%AMAT-2.21%0005.HK-0.78%AP2d-1.57%UNH-0.63%DELL-2.88%HSBA.L-1.01%MS+0.01%PG-0.28%GE+0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.34%HD-1.11%GS-0.18%0939.HK+1.66%NZDJPY-2.68%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.50%GBPJPY-1.39%EURJPY-1.37%CADJPY-1.36%EURNZD+1.36%NZDCAD-1.34%GBPNZD+1.31%NZDUSD-1.21%NZDCHF-1.04%USDNOK+0.91%EURNOK+0.87%CHFNOK+0.78%AUDNZD+0.75%USDZAR+0.68%USDSEK+0.68%NOKJPY-0.67%EURZAR+0.64%EURSEK+0.64%AUDDKK-0.63%AUDCAD-0.62%EURAUD+0.60%GBPAUD+0.55%GBPZAR+0.55%CHFSEK+0.54%AUDSGD-0.50%AUDUSD-0.46%USDTHB+0.45%USDMXN+0.42%GBPTRY+0.41%NZDSGD-0.32%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%AUDCHF-0.28%GBPCHF+0.27%USDPLN+0.25%AUDNOK+0.24%EURPLN+0.20%USDCHF+0.19%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.09%NZDMXN-0.08%SGDJPY+0.07%USDCNH+0.05%EURHKD-0.05%EURGBP+0.04%GBPCAD-0.04%USDCOP-0.04%EURCNH+0.04%USDDKK+0.03%GBPSGD+0.03%CHFSGD+0.03%USDHKD+0.01%PLNJPY-0.01%EURDKK-0.01%EURCAD0.00%XPTUSD-4.74%HG1-4.47%GAGUSD-4.15%XAGUSD-4.14%UKOIL+3.54%USOIL+3.11%SUGAR+1.50%XAUUSD-0.98%GAUUSD-0.98%COFFEE-0.76%COTTON+0.66%S1+0.65%BTCUSD-1.21%ETHUSD-1.02%USDTUSD-0.02%XRPUSD-2.60%SOLUSD-1.48%TRXUSDT0.00%ZECUSDT-5.54%DOGEUSD-2.81%XMRUSDT-1.66%LINKUSD-1.09%XLMUSD-1.92%BCHUSDT-10.38%LTCUSD-1.72%UNIUSD-3.29%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.41%TAOUSDT-5.10%AAVEUSD-2.76%DOTUSDT-3.34%ICPUSDT-0.79%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.35%ARBUSDT+1.64%JUPUSDT-2.96%INJUSDT-4.80%STXUSDT-3.07%FETUSDT-3.57%TIAUSDT-0.87%PYTHUSDT+0.14%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.40%OPUSDT-3.00%IOTAUSDT-3.76%POLUSDT-5.71%AXSUSDT-2.47%FARTCOINUSDT-2.75%EOSUSDT-0.93%DYDXUSDT-0.80%ORDIUSDT-0.83%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.39%AAPL+2.31%GOOGL+0.10%MSFT-0.02%AMZN+0.06%TSM-0.72%SPCX+1.69%AVGO-0.04%META+0.40%TSLA-0.45%SKHY-3.99%MU-4.17%BRK-B-0.06%LLY+0.40%JPM-0.38%AMD-2.33%WMT+0.16%V-0.25%XOM-0.26%ASMLa-1.56%JNJ-0.22%INTC-4.20%MA-0.59%0700.HK-1.94%ORCL-2.03%1398.HK+0.79%BAC-0.26%ABBV+0.52%CSCO-0.44%CVX-0.51%COST-0.10%LRCX-3.66%KO+0.59%CAT-0.99%AMAT-2.21%0005.HK-0.78%AP2d-1.57%UNH-0.63%DELL-2.88%HSBA.L-1.01%MS+0.01%PG-0.28%GE+0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.34%HD-1.11%GS-0.18%0939.HK+1.66%NZDJPY-2.68%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.50%GBPJPY-1.39%EURJPY-1.37%CADJPY-1.36%EURNZD+1.36%NZDCAD-1.34%GBPNZD+1.31%NZDUSD-1.21%NZDCHF-1.04%USDNOK+0.91%EURNOK+0.87%CHFNOK+0.78%AUDNZD+0.75%USDZAR+0.68%USDSEK+0.68%NOKJPY-0.67%EURZAR+0.64%EURSEK+0.64%AUDDKK-0.63%AUDCAD-0.62%EURAUD+0.60%GBPAUD+0.55%GBPZAR+0.55%CHFSEK+0.54%AUDSGD-0.50%AUDUSD-0.46%USDTHB+0.45%USDMXN+0.42%GBPTRY+0.41%NZDSGD-0.32%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%AUDCHF-0.28%GBPCHF+0.27%USDPLN+0.25%AUDNOK+0.24%EURPLN+0.20%USDCHF+0.19%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.09%NZDMXN-0.08%SGDJPY+0.07%USDCNH+0.05%EURHKD-0.05%EURGBP+0.04%GBPCAD-0.04%USDCOP-0.04%EURCNH+0.04%USDDKK+0.03%GBPSGD+0.03%CHFSGD+0.03%USDHKD+0.01%PLNJPY-0.01%EURDKK-0.01%EURCAD0.00%XPTUSD-4.74%HG1-4.47%GAGUSD-4.15%XAGUSD-4.14%UKOIL+3.54%USOIL+3.11%SUGAR+1.50%XAUUSD-0.98%GAUUSD-0.98%COFFEE-0.76%COTTON+0.66%S1+0.65%BTCUSD-1.21%ETHUSD-1.02%USDTUSD-0.02%XRPUSD-2.60%SOLUSD-1.48%TRXUSDT0.00%ZECUSDT-5.54%DOGEUSD-2.81%XMRUSDT-1.66%LINKUSD-1.09%XLMUSD-1.92%BCHUSDT-10.38%LTCUSD-1.72%UNIUSD-3.29%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.41%TAOUSDT-5.10%AAVEUSD-2.76%DOTUSDT-3.34%ICPUSDT-0.79%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.35%ARBUSDT+1.64%JUPUSDT-2.96%INJUSDT-4.80%STXUSDT-3.07%FETUSDT-3.57%TIAUSDT-0.87%PYTHUSDT+0.14%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.40%OPUSDT-3.00%IOTAUSDT-3.76%POLUSDT-5.71%AXSUSDT-2.47%FARTCOINUSDT-2.75%EOSUSDT-0.93%DYDXUSDT-0.80%ORDIUSDT-0.83%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
TB

Tyra Biosciences, Inc. (TYRA)

NASDAQ • Healthcare

$22.01
-$4.71 (-17.7%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$18.94
Previous Close$22.01
Day Range$18.66 - $22.3
Avg. Volume (3M)799.7K
Market Cap$1.3B
52 Week Range
$11.7$40.65
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$148.5M
EPS (TTM)
-$2.4
ROA (TTM)
-38.75%
Current Ratio
14.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-5.6%Q1 2026-$0.57
-6.7%Q2 2026-$0.64
-6.2%Q3 2026-$0.69
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.2%

Tyra Biosciences’ EPS trailed expectations in the second fiscal quarter of 2026, with results reported August 4, 2026 based on preliminary figures, as EPS came in at -$0.69 versus the -$0.65 estimate (difference -$0.04). Net income was a loss of roughly $45.6 million, down -62.1% year over year from a loss of about $28.1 million, while EPS declined -46.8% from -$0.47 a year ago. The company posted an operating loss of about $49.0 million as it continues development work in targeted oncology programs such as TYRA-300, and it generated negative operating cash flow of roughly $31.1 million during the quarter. For the next period, consensus calls for EPS of -$0.69.

View full earnings history

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops targeted cancer medicines. Trading as TYRA, the company is a small-cap drug developer built around precision therapies for oncology, with work centered on overcoming tumor resistance rather than on a marketed product base.

Name
Tyra Biosciences, Inc.
CEO
Todd Harris
Website
www.tyra.bio
Industry
Healthcare
Year Founded
2018
Employees
87

Today's Snapshot

AI-generated

TYRA opened 2.7% below yesterday's close, while its sector was flat. Tyra’s bladder-cancer trial produced fewer responses than investors expected.

Trading Volume

Below 10d avg (1.2M)

352.4K

vs S&P 500 Today

Strong Outperformance

+5.60%

Updated: September 10, 2026 at 14:40 UTC

Technical Indicators

0 Buy2 Neutral6 Sell
TYRA is trading near 22.29 and registers a clear technical sell profile, with prices well below short-, medium- and long-term moving averages and momentum measures sharply negative—CCI and MACD both register strong sell readings—while ADX near 27.4 confirms a pronounced downtrend. On-balance volume shows distribution, reinforcing downside pressure, and volatility is elevated with an ATR around 2.06 (about 9.3%), which increases risk on moves lower. The confluence of weak momentum, heavy volume bias and strong trend supports the strong sell designation. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$24.87 - $28.91
    Sell
  • RSI (14)36.07
    Neutral
  • Stochastic %K (14, 3, 3)37.18
    Neutral
  • MACD Level (12, 26)-1.14
    Sell

Peers & Related Assets

MRVIMaravai LifeSciences Holdings, Inc.
$6.95-3.3%
SVRASavara Inc.
$5.42-2.0%
KURAKura Oncology, Inc.
$12.09-3.4%
GERNGeron Corporation
$1.4-7.3%
PRMEPrime Medicine, Inc.
$3.47-2.5%
EYPTEyePoint Pharmaceuticals, Inc.
$4.34-4.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.